10/19/2005 5:11:28 PM
MultiCell Technologies Inc. (the Company) (OTCBB:EXTI) announced further public presentations of the Company's patented cell lines this week.
Dr. Andrew Parkinson, founder and chief executive officer of XenoTech LLC of Lenexa, Kan., the Company's licensee, presented "Immortalized Hepatocytes: A New In Vitro Approach to Early Compound Screening" in the Break-Through Technologies Session of the Cell Based Assays for HTS Symposium in Philadelphia, Pa. May 18, 2004. Dr. Parkinson's talk discussed MultiCell's new human hepatocyte line and its potential to solve the supply and inter-individual variability issues that restrict the use of human hepatocytes for candidate comparisons in preclinical metabolism, toxicity and induction studies, stating that its unlimited supply assures long-term reproducibility and scheduling convenience in utilizing this breakthrough technology.
XenoTech LLC is also exhibiting at the 3rd International Bio Expo Japan 2004 held together with INTERPHEX Japan in Tokyo May 19-21.
comments powered by